Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
A study published by researchers at the University of Chicago Medical Center found that prenatal exposure to methamphetamine increases the risk of brain disorders, such as Parkinson's disease, in male offspring who later take the drug themselves. The toxic effects of methamphetamine can hasten the onset of these conditions.
Researchers found that pramipexole prevented nearly 100% of brain cells from dying in mice with a Parkinson's-like condition. The drug also showed neurotrophic effects by increasing dopamine cell size, suggesting potential as a neuroprotective agent.
A study of 15 professional welders found they developed typical clinical signs of Parkinson's disease 15 years earlier than the general population. Brain imaging scans revealed no significant difference in dopamine levels between the welders and control patients, suggesting a possible environmental link.
Scientists have found a link between the combination of two widely used agricultural pesticides and Parkinson's disease in mice. The study, led by Deborah Cory-Slechta, suggests that everyday environmental factors may play a role in the development of the disease.
A new study published in Neurology found that selegiline, a drug used to treat Parkinson's disease, does not increase the risk of death for patients taking levodopa. The study compared the death rates of 97 patients with Parkinson's who received selegiline treatment with those of 902 people without the disease.
A recent study found that men are twice as likely to develop Parkinson's disease compared to women. The risk of developing the disease increases with age for both men and women. Researchers are still unsure why Parkinson's is more common in men, but one theory suggests that estrogen may protect women from the disease.
A study of 196 people with and without Parkinson's disease found that coffee use was associated with a lower risk of developing the disease. Heavier coffee drinkers exhibited fewer instances of the disease, while tobacco chewers and alcoholics were also less likely to develop the condition.
Researchers found that alpha-synuclein, a key component of Parkinson's lesions, is targeted by oxidative stress, specifically nitration. This discovery provides conclusive evidence for the role of oxidative damage in neurodegenerative diseases like Parkinson's and Alzheimer's.
Researchers used gene therapy to deliver GDNF directly to the brain cells of monkeys, resulting in a dramatic increase in dopamine production and prevention of disease progression. The treatment also reversed functional deficits and symptoms associated with Parkinson's disease.
Researchers found that up to 96% of Parkinson's patients experience serious sleep disturbances, often overlooked by doctors. A new study suggests that cabergoline, a long-acting dopamine agonist, offers significant benefits in improving symptoms of sleep disturbance and daytime sleepiness.
A new study published in JAMA found that initiating therapy with MIRAPEX delayed the onset of motor complications and reduced their incidence compared to patients on initial treatment with levodopa. At two years, 72% of MIRAPEX-treated patients were free from motor complications.
Researchers found that pramipexole, a dopamine agonist, reduces debilitating complications in Parkinson's patients. However, it may not control disease symptoms as well as levodopa, which carries more side effects.
Italian researchers found that workers exposed to hydrocarbon solvents, such as petroleum-based products, were three years younger when first showing symptoms. The severity of Parkinson's disease was directly related to the amount of exposure experienced.
A new study reveals Parkinson's disease is associated with a loss of norepinephrine-producing nerve endings in the heart, improving understanding of the disorder's development and potential prevention. This finding also sheds light on orthostatic hypotension, a common complication characterized by dizziness and fainting.
Researchers have identified a compound in tobacco that inhibits an enzyme that breaks down key brain chemicals, potentially offering protection against Parkinson's disease. The discovery opens up new avenues of research and may lead to the development of neuroprotective compounds.
ReQuip significantly reduces the risk of levodopa-induced dyskinesia in Parkinson's disease patients. The five-year study shows that ReQuip monotherapy can reduce dyskinesia incidence by seven times and effectively control early PD symptoms.
A study published in The New England Journal of Medicine confirms Requip's efficacy in managing early Parkinson's disease symptoms with a low risk of developing dyskinesias. Patients taking Requip alone were seven times more likely to remain dyskinesia-free than those on levodopa alone.
A study by Emory University neurologists found that pallidotomy surgery significantly improves motor function in patients with Parkinson's disease, with persistent benefits extending to both sides of the body. The long-term effectiveness of this treatment has been confirmed through a 36-month follow-up.
Researchers found that people exposed to pesticides were approximately two times more likely to develop Parkinson's disease than those not exposed. In-home exposure to insecticides carried the highest risk of developing the disease.
Researchers found a link between smoking, coffee consumption, and lower Parkinson's disease incidence. Higher dopamine levels in the brain may explain why people with these habits are less likely to develop Parkinson's.
Researchers have discovered that synuclein plays a crucial role in communication between neurons, potentially shedding light on the mechanisms underlying Parkinson's and Alzheimer's diseases. The study provides strong evidence that synucleins control the release of neurotransmitters from nerve cells.
Scientists have identified a tobacco compound that may explain why smokers are less vulnerable to Parkinson's disease. The naphthoquinone derivative works by interfering with an enzyme in the brain that breaks down neurotransmitters.
Researchers have created a fly model of Parkinson's disease, replicating the dense protein inclusions and symptoms of the disease. The flies exhibit loss of dopamine-producing neurons and motor deficits, similar to those found in humans, making them an ideal model for testing new drugs and therapeutic approaches.
Researchers are conducting a national genetic study to identify the genetic markers that contribute to Parkinson's disease. The study aims to enroll 600 pairs of siblings with Parkinson's disease, using information from the U.S. Human Genome Project to isolate genetic markers.
A new transgenic mouse model has been developed to simulate Parkinson's disease and related disorders, including Alzheimer's disease. The model shows impaired motor function and protein deposits in specific brain regions associated with the diseases, offering a new tool for studying and treating these conditions.
A new study found that pallidotomy surgery, a procedure to reduce tremors in Parkinson's sufferers, also improves speech volume in some patients. Seven out of 12 patients with mild speech problems showed significant improvements following the surgery.
Yale researchers have created a new method to record electrical activities within living cells, providing insights into degenerative neurological diseases like Parkinson's. The technique, which allows scientists to study inaccessible parts of cells, has already led to findings on how neurons learn and remember.
A Mayo Clinic study highlights the importance of autopsy in diagnosing Parkinson's disease, suggesting low autopsy rates and nonrandom patterns may skew research findings. The study analyzed 235 deceased patients with parkinsonism diagnoses, revealing important factors influencing autopsy decisions.
A landmark study shows ReQuip reduces dyskinesia risk by 15-fold compared to L-dopa, with comparable symptom control and lower required doses. The treatment has improved patient outcomes and reduced CNS adverse experiences.
A 5-year clinical trial led by Thomas Jefferson University aims to investigate the effects of GM1 ganglioside on improving Parkinson's disease symptoms, delaying disease progression, and restoring damaged brain cells. The study will compare the drug to standard treatments, using advanced imaging techniques to visualize dopamine termina...
Researchers developed a method to identify high-risk individuals with Parkinson's disease using SPECT brain imaging and beta CIT radiopharmaceutical. They differentiated between Parkinson's patients and controls, as well as relatives of Parkinson's patients, with reduced drug binding.
A new Mayo Clinic study finds that parkinsonism affects 7.5% of the population, with men twice as likely to develop it as women. The study reveals that Parkinson's disease accounts for only 42% of all parkinsonism cases.
A laser pointer has been found to help some Parkinson's patients overcome freezing episodes, where their legs temporarily lock in place. The device provides a visual cue that helps patients take the next step towards regaining mobility, offering hope for those struggling with this debilitating symptom.
A recent clinical trial found that fetal dopamine cell implants improved movement control in younger Parkinson's patients, but had no significant impact on older patients or daily activities. PET brain scans revealed increased dopamine activity in those who received the implants, but also showed more severe adverse experiences.
A recent study examining 19,842 white male twins found that genetic factors do not play a significant role in causing the most common form of Parkinson's disease. Instead, undetermined environmental factors are believed to trigger typical PD, particularly among those diagnosed after age 50.
Three university hospitals will receive funding to advance understanding of Parkinson's disease and develop new treatments. Investigators will study the cause of the disease, diagnose and treat it, and provide training for young scientists.
Researchers at Virginia Tech will study the potential connection between pesticide exposure during the Persian Gulf War and an increased risk of developing Parkinson's Disease. The three-year project aims to investigate neurochemical changes in mice exposed to insecticides, which could provide insights into the disease.
Researchers at Emory University have identified a potential new approach for alleviating Parkinson's disease symptoms by blocking glutamate receptors in the brain. This could lead to combination therapies that improve treatment outcomes and reduce side effects.
Researchers discovered a gene-toxin link that may increase the risk of dementia in Parkinson's patients. The study found that exposure to pesticides and a defective gene called CYP 2D6 29B+ increased the likelihood of developing dementia, particularly among those with Parkinson's disease with dementia (PD+D).
Researchers at Thomas Jefferson University found that a naturally occurring substance in the cell membrane, GM1 ganglioside, improved symptoms in Parkinson's disease patients and slowed progression. The study showed significant differences in motor abilities between those who received the drug and those who did not.
Researchers have discovered an imaging agent called Altropane that visualizes nerve loss in Parkinson's patients, providing a faster and cheaper alternative to existing methods. The study suggests that Altropane can help identify presymptomatic patients for experimental treatments and track disease progression.
Researchers at Thomas Jefferson University have developed a non-invasive gamma knife treatment that shows comparable results to surgery in alleviating Parkinson's disease symptoms. The treatment uses high doses of radiation to destroy targeted areas of the brain, potentially offering an alternative to traditional surgical options.
Dystonia results from a deficiency in dopamine receptors, according to researchers at Washington University School of Medicine. A study found that dopamine levels were 97-98% lower on the treated side of the brain during dystonic symptoms.
Researchers successfully delivered genes encoding dopamine-producing enzymes into the brains of rats with induced Parkinson's disease, significantly reducing abnormal rotational movement. The treatment showed greater improvement when both genes were used together.
Researchers found that pallidotomy surgery for Parkinson's disease improves brain activity in areas responsible for controlling movement and decreases abnormal activation in cerebral areas. The study provides new insight into the brain mechanisms responsible for symptomatic improvement following surgery.
The new Parkinson's disease drug pramipexole dihydrochloride has been shown to reduce symptoms by 20% in patients, with a more precise target on the specific dopamine receptor involved. The drug also appears to be better tolerated than current options, offering hope for improved treatment outcomes.
Scientists at the NIH have identified a gene abnormality causing some cases of Parkinson's disease, which affects nerve cells and dopamine production. The discovery provides a new tool for understanding cellular abnormalities in Parkinson's disease and connects it to research on Alzheimer's disease.
A study published in Neurology has identified long-term exposure to copper and manganese as a significant risk factor for developing Parkinson's disease. The study found that occupational exposure to these metals, either alone or in combination with other metals like lead and iron, increased the risk of acquiring the disease.
A team of researchers has made a promising discovery using gene therapy to protect dopamine-producing neurons in the brain from Parkinson's disease. The study found that injecting a modified virus carrying a specific gene into the brain led to improved neuron survival rates.
New research suggests that Lewy bodies may entrap life-sustaining cellular organelles, leading to neuronal death in diseases such as Parkinson's and ALS. The study provides a potential strategy for developing treatments by targeting the formation or elimination of Lewy bodies.
Researchers localized the gene responsible for Parkinson's disease to a small region of chromosome 4, marking a significant advancement in understanding the disease. This finding is based on a large family study with multiple cases of Parkinson's disease over several generations.
Researchers identify a gene on chromosome 4 as a potential cause of Parkinson's disease, shedding light on the mysterious origins of this debilitating condition. The discovery may lead to genetic testing, early diagnosis, and treatment options for all forms of Parkinson's disease.
Researchers suggest that cells are programmed to self-destruct when isolated from their neighbors, potentially providing a key to fighting cancer and autoimmune diseases. This discovery could lead to new treatments by understanding how to disrupt the cell's suicidal tendencies.
Researchers created a mouse model by deleting the gene for dopamine transporter, leading to an overstimulation of brain signals. This study provides a new tool to understand addiction mechanisms and develop treatments for psychiatric disorders and Parkinson's disease.